Company: NCEL
Filing Date: 2025-04-15
Form Type: 425
Source: 0001213900-25-031780
Chunk: 3

Company: NewcelX Ltd.
Filing Date: 2025-04-15
Form: 425
Chunk 3
---
 findings represent a
significant milestone in our strategic expansion into substance use disorders,” said Alex Zwyer, Chief Executive Officer of NLS Pharmaceutics. “The ability of Mazindol ER to blunt the rewarding effects of fentanyl highlights its potential as a treatment
for those with substance use disorders.”

About NLS Pharmaceutics Ltd.

NLS Pharmaceutics Ltd. is a Swiss clinical-stage
biopharmaceutical company dedicated to developing innovative treatments for CNS disorders, including ADHD, narcolepsy, and substance use
disorders. The Company’s lead compound, Mazindol ER, is being investigated across several indications due to its unique pharmacological
action on monoaminergic, opioid, serotonergic, and orexinergic systems.

<div align='center'>2</div>

About Kadimastem

Kadimastem is a clinical stage cell therapy company,
developing “off-the-shelf”, allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation
of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the company’s lead product, is an astrocyte cell therapy in
clinical development for the treatment for ALS and in pre-clinical studies for other neurodegenerative indications.

IsletRx is the company’s treatment for diabetes.
IsletRx is comprised of functional pancreatic islet cells producing and releasing insulin and glucagon, intended to treat and potentially
cure patients with insulin-dependent diabetes. Kadimastem was founded by Professor Michel Revel, Chief Scientific Officer of Kadimastem
and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention
and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange
(TASE: KDST).

Safe Harbor Statement

This press release contains expressed or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, NLS is using forward-looking statements when it discusses the use of Mazindol as a potential novel treatment for fentanyl dependence, regulatory approval timelines, clinical trial outcomes, market acceptance and its expected preclinical program. Further, NLS and Kadimastem are using forward-looking statements when they discuss the expected closing of the transaction and the potential benefits of the transaction to NLS and Kadimastem and their respective shareholders, as well as the expected strategic position of the combined company following the merger